The company just released its 2020 annual report.New funding agreements increased the company's liquidity and gave Hamlet Protein flexibility to continue growing, said CEO...
The CAB will lead and advise Genprex as it advances its REQORSA immunogen therapy program, including its Acclaim clinical trials in non-small cell lung...